Q1 FY27 results: consol PAT up 29% YoY; Rs 150 cr BSV guarantee approved

Emphasis Of MatterResults RestatedPat Growth 25pctRelated Party TransactionsContingent Liabilities IncreasedResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹2590.10

prior close

₹2570.20

announcement price

In-mkt

timing

Nifty Midcap 150market-0.4%-0.4% vs market

Pharmaceuticals peers, median of 162sector-0.7%-0.1% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.4-0.4-0.7-0.1

Next day

-4.6+0.1-4.6-0.5-4.1

-4.1+1.3-5.4+0.2-4.3

-5.2+1.0-6.2+0.1-5.3

-5.8+1.2-7.0+0.5-6.3

-6.6+0.8-7.4+0.7-7.3

-5.9+1.5-7.4+1.4-7.3

15d

-7.9+1.1-9.1+0.4-8.3

-6.6+1.8-8.4+1.7-8.3

-3.3-5.4+2.1+3.0-6.4

-3.8pendingpending-2.4-1.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma Q1 FY27 standalone revenue Rs 2,964 cr (up about 15% YoY on restated basis), PAT Rs 558 cr. Consolidated revenue Rs 4,031 cr, PAT Rs 574 cr (up 29% YoY on restated basis). Board approved Rs 150 cr corporate guarantee for wholly owned subsidiary Bharat Serums and Vaccines and sale of Broadway Hospitality for Rs 49 cr. Q1 FY26 numbers restated to reflect BSV womens health portfolio acquisition. Auditor flagged pending income tax appeals involving adjustments of about Rs 1,869 cr.

Likely market impact

Strong consolidated PAT growth offsets a standalone PAT decline; new Rs 150 cr guarantee and pending Rs 1,869 cr tax dispute are key risks to watch.